Lipocine shareholders approve reduction in authorized shares from 200M to 75M

Lipocine Inc.

Authorized common stock reduced from 200M to 75M shares; Certificate of Amendment filed June 4, 2025.
All six director nominees elected: Dr. Mahesh V. Patel, Jeffrey A. Fink, John W. Higuchi, Dr. Jill M. Jene, Dr. Richard Dana Ono, Dr. Spyros Papapetropoulos.
Tanner LLC ratified as independent auditor for FY 2025 with 2,817,444 votes for, 86,618 against.
Non-binding advisory vote on executive compensation passed: 926,497 for, 121,032 against.

item 5.03item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.